The determination of an ADHD treatment regimen can be time-consuming, requiring gradual upward dose titration and trial and error and often resulting in delays in symptom remission, premature termination of treatment, and frustration.
Children with attention problems in the first period experienced greater changes in food responses, emotional overeating, and satiety responsiveness by the second period.
Children receiving ADHD medication were older, had a higher prevalence of autism, and had more comorbid conditions than children not receiving medication.
Healthcare utilization and expenditures on psychiatric and somatic disorders at 18 years were significantly higher in patients with a childhood diagnosis of ADHD for most outcomes.
Nearly 14 percent of children aged 3 to 17 years had ever been diagnosed with attention-deficit/hyperactivity disorder or a learning disability in 2016 to 2018.
In a Society for Developmental and Behavioral Pediatrics Clinical Practice Guideline, recommendations are presented for the management of complex ADHD in childhood.
The percentage of patients with an ADHD prescription between their 16th and 19th birthdays decreased by 19% in all patients.
After controlling for depression, irritability, and anxiety, the investigators found no direct effect of ADHD symptoms on suicidality.
Akili Interactive announced topline data from an open-label study (STARS-ADHD Adjunctive) of AKL-T01 for the treatment of attention deficit hyperactivity disorder in children with or without use of stimulants.
US drug companies have started the new year by raising the prices of hundreds of medications.